Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 183

The DOI matches its Crossref record.

Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction

Open access
Okumura, Naoki, Sakamoto, Yuji, Fujii, Keita, Kitano, Junji, Nakano, Shinichiro, Tsujimoto, Yuki, Nakamura, Shin-ichiro, Ueno, Morio, Hagiya, Michio, Hamuro, Junji, Matsuyama, Akifumi, Suzuki, Shingo, Shiina, Takashi, Kinoshita, Shigeru, Koizumi, Noriko · 2016 · Scientific Reports

Abstract

The corneal endothelium maintains corneal transparency; consequently, its dysfunction causes severe vision loss. Tissue engineering-based therapy, as an alternative to conventional donor corneal transplantation, is anticipated to provide a less invasive and more effective therapeutic modality. We conducted a preclinical study for cell-based therapy in a primate model and demonstrated regeneration of the corneal endothelium following injection of cultured monkey corneal endothelial cells (MCECs) or human CECs (HCECs), in combination with a Rho kinase (ROCK) inhibitor, Y-27632, into the anterior chamber. We also evaluated the safety and efficacy of Good Manufacturing Practice (GMP)-grade HCECs, similar to those planned for use as transplant material for human patients in a clinical trial and we showed that the corneal endothelium was regenerated without adverse effect. We also showed that CEC engraftment is impaired by limited substrate adhesion, which is due to actomyosin contraction induced by dissociation-induced activation of ROCK/MLC signaling. Inclusion of a ROCK inhibitor improves efficiency of engraftment of CECs and enables cell-based therapy for treating corneal endothelial dysfunction as a clinically relevant therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep26113

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 183

Metadata

Authors
Okumura, N., Sakamoto, Y., Fujii, K., Kitano, J., Nakano, S., Tsujimoto, Y., Nakamura, S.-I., Ueno, M., Hagiya, M., Hamuro, J., Matsuyama, A., Suzuki, S., Shiina, T., Kinoshita, S., & Koizumi, N.
Venue
Scientific Reports
Published
2016-05-18
Volume
6
Issue
1
Pages
26113-26113
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2405135753
Cited by
183
References
0
FWCI
16.03
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction. https://app.cochat.ai/papers/10.1038/srep26113
The paper
Okumura, N., Sakamoto, Y., Fujii, K., Kitano, J., Nakano, S., Tsujimoto, Y., Nakamura, S.-I., Ueno, M., Hagiya, M., Hamuro, J., Matsuyama, A., Suzuki, S., Shiina, T., Kinoshita, S., & Koizumi, N. (2016). Rho kinase inhibitor enables cell-based therapy for corneal endothelial dysfunction. Scientific Reports. https://doi.org/10.1038/srep26113

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.